United States Patent 7,947,654: Desmopressin Orodispersible Dosage Forms, Claim Scope and Patent Landscape

US 7,947,654 protects a narrow desmopressin product concept: a solid orodispersible dosage form containing 10 to 600 micrograms of desmopressin acetate, measured as free-base desmopressin, that disintegrates in the mouth within 10 seconds. Dependent claims add sublingual use, freeze-dried manufacture, an open matrix carrier, gelatin, fish gelatin, non-gelling fish gelatin, and packaging with sublingual instructions.

The patent is strongest against products that combine all of those features in a rapidly disintegrating lyophilized orodispersible tablet. It is materially weaker against conventional tablets, oral solutions, nasal products, injectables, products outside the claimed dose range, and products that do not meet the 10-second disintegration limitation.

What does US Patent 7,947,654 protect?

The independent product claim protects a dosage form with four required elements:

Claim 1 limitation	Scope
Solid pharmaceutical dosage form	Excludes liquids, sprays, and injectable solutions
Orodispersible	Must disperse or disintegrate in the mouth
10 to 600 micrograms desmopressin acetate, measured as free base	Defines the active-ingredient range
Disintegration within 10 seconds	Adds a performance limitation

The claim does not require sublingual administration, freeze drying, gelatin, fish gelatin, or a particular tablet geometry. Those features appear in dependent claims 2 through 8.

The product must satisfy every limitation of claim 1 for literal infringement. A competing product containing 601 micrograms, for example, would fall outside the express dose range, although formulation-labeling, assay variability, and the doctrine of equivalents could affect an infringement analysis.

What dose range does claim 1 cover?

The claim covers 10 to 600 micrograms of desmopressin measured as free base. The reference to free base prevents a party from avoiding the dose limitation merely by reporting the heavier acetate salt.

Using approximate molecular weights, 10 to 600 micrograms of desmopressin free base corresponds to roughly 11 to 664 micrograms of desmopressin acetate, subject to the specific salt and hydration state used in the product. The claim's controlling measurement is the free-base amount, not the gross mass of desmopressin acetate salt.

The dose range is broad enough to cover typical low-dose nocturia and enuresis products, while excluding higher-dose conventional desmopressin tablets and many parenteral presentations.

How do claims 2 through 9 narrow the patent scope?

Claim 2: sublingual administration

Claim 2 covers the claim 1 dosage form when adapted for placement under the tongue. A product marketed only for ordinary buccal or general oral administration may not satisfy this limitation. A product label, patient instructions, tablet design, and pharmacokinetic rationale could all be relevant to whether the dosage form is “adapted” for sublingual use.

Claims 3 and 4: sublimation and freeze drying

Claim 3 requires a dosage form obtainable by subliming solvent from a composition containing:

desmopressin acetate;
a solution of carrier material in a solvent; and
a composition in the solid state in a mold.

Claim 4 narrows claim 3 to sublimation carried out by freeze drying. These claims target a lyophilized dosage-form manufacturing route rather than a compressed-tablet process.

A compressed tablet containing the same active ingredient and dose would not ordinarily satisfy claims 3 or 4 unless the accused product was in fact made through the claimed sublimation or freeze-drying process. The “obtainable by” language creates a product-by-process issue. For infringement purposes, the relevant question is whether the resulting product falls within the claimed product definition and whether the process limitation is treated as limiting under the applicable claim-construction analysis.

Claims 5 through 8: open matrix and gelatin technology

Claim 5 requires an open matrix network carrying desmopressin. The matrix must comprise a water-soluble or water-dispersible carrier material that is inert toward desmopressin.

Claim 6 specifies gelatin. Claim 7 specifies fish gelatin. Claim 8 further requires non-gelling fish gelatin.

This sequence creates a narrowing hierarchy:

Claim	Added limitation
5	Open matrix with inert water-soluble or water-dispersible carrier
6	Gelatin carrier
7	Fish gelatin
8	Non-gelling fish gelatin

Claims 7 and 8 are technically narrower but may be commercially important because fish gelatin and non-gelling fish gelatin can influence dissolution, matrix strength, taste, stability, and manufacturing performance. A competitor using mannitol, pullulan, maltodextrin, or another carrier may avoid claims 6 through 8 while potentially remaining exposed under claim 1 or claim 5.

Claim 9: pack and instructions

Claim 9 covers a pack containing the claim 1 dosage form together with instructions to place it beneath the tongue.

This claim introduces a packaging and labeling combination. It may be relevant to marketed products even where the dosage-form manufacturer does not directly supply the patient instructions. Enforcement would depend on the conduct of the relevant manufacturer, marketer, distributor, and healthcare channel, as well as applicable inducement and divided-infringement principles.

What products are outside the principal claim?

Several desmopressin products generally fall outside the literal scope of claim 1:

Product type	Likely position under claim 1
Conventional swallowed tablet	Outside if it does not disintegrate within 10 seconds
Oral solution	Outside because it is not a solid dosage form
Nasal spray	Outside
Injectable desmopressin	Outside
Higher-dose conventional tablet	Outside if above 600 micrograms free base
Product disintegrating after more than 10 seconds	Outside the express performance limitation
Sublingual lyophilized tablet within the dose range	High exposure
Freeze-dried fish-gelatin wafer within the dose range	Highest exposure under claims 1 and 4 through 8

The principal design-around opportunities are dose selection, dosage-form architecture, disintegration time, carrier selection, and manufacturing method. A competitor should not rely on carrier substitution alone if its product remains a solid orodispersible dosage form within the claimed dose range and satisfies the 10-second limitation.

How strong is the patent estate for desmopressin orodispersible products?

The claims are commercially focused but technically fragmented. Claim 1 provides the broadest practical protection, while claims 2 through 9 create narrower fallback positions.

Strengths

Performance-based protection. The 10-second disintegration requirement can capture products that use different excipients but deliver the same rapid oral-dispersion function.
Dose coverage. The 10 to 600 microgram free-base range covers commercially relevant low-dose desmopressin products.
Product protection. Claim 1 is not limited to a named brand, manufacturer, or particular excipient.
Sublingual commercialization. Claims 2 and 9 connect the dosage form to product labeling and patient-use instructions.
Manufacturing fallback claims. Claims 3 and 4 address lyophilization, while claims 5 through 8 address matrix composition.

Weaknesses

Narrow dosage-form requirement. Conventional tablets and liquids are generally outside claim 1.
Objective testing burden. The 10-second limitation requires a defined test method, conditions, sample size, and endpoint.
Potential dose-range design around. Products outside the claimed range may avoid literal infringement.
Process-specific dependent claims. Claims 3 and 4 are less useful against products made by compression, molding, spray drying, or another non-sublimation process.
Narrow gelatin claims. Fish-gelatin claims do not reach products using non-gelatin carriers.
Claim 9 enforcement complexity. The pack-and-instructions claim may raise questions concerning which party supplies the instructions and performs the relevant acts.

What patents protect competing desmopressin products?

Desmopressin has been commercialized in several dosage forms, including oral tablets, nasal spray, injectable formulations, and rapidly disintegrating oral products. The relevant patent landscape should be separated by technology rather than treated as one undifferentiated desmopressin estate.

Technology	Typical patent focus	Relationship to US 7,947,654
Conventional oral tablets	Composition, dose, treatment method	Usually outside the solid-orodispersible limitation
Nasal formulations	Spray device, concentration, dosing, preservation	Outside claim 1
Injectable formulations	Sterility, concentration, container system	Outside claim 1
Lyophilized oral wafers	Matrix, freeze drying, rapid dispersion	Directly relevant
Sublingual low-dose products	Dose, absorption, nocturia treatment	Directly relevant
Fish-gelatin matrices	Carrier and matrix composition	Relevant to claims 7 and 8
Manufacturing processes	Freeze drying, mold filling, solvent sublimation	Relevant to claims 3 and 4
Packaging and labeling	Sublingual instructions and administration	Relevant to claim 9

The central competitive question is whether a product is a low-dose, rapidly disintegrating solid intended for placement in the mouth. Products outside that category compete clinically but do not necessarily create patent risk under this patent.

What is the FDA and Orange Book relevance?

US 7,947,654 is a small-molecule drug patent, not a biologic patent. Biosimilar procedures under the Public Health Service Act are therefore not the principal pathway for a competing desmopressin product. A generic competitor would ordinarily consider an abbreviated new drug application, subject to the reference product, applicable exclusivity, listed patents, and the product's dosage form.

Orange Book relevance depends on whether the patent is listed against a particular approved new drug application. Patent issuance alone does not establish Orange Book listing, and the scope of an Orange Book listing is separate from the scope of the claims. A listed patent may be challenged through a Paragraph IV certification if the applicant asserts that the patent is invalid, unenforceable, or not infringed.

For a desmopressin orodispersible product, the relevant regulatory questions are:

whether the reference product is approved as an orally disintegrating or sublingual tablet;
whether the patent is listed against that reference product;
whether the patent term has expired;
whether pediatric or other regulatory exclusivity remains;
whether the ANDA applicant makes a Paragraph IV certification;
whether the NDA holder files suit within 45 days; and
whether a 30-month stay or other litigation-related delay applies.

The patent claims supplied do not establish the patent's Orange Book listing status, Paragraph IV history, litigation history, or current enforceability. Those issues arise from FDA and court records rather than from claim language.

When does US 7,947,654 lose exclusivity?

Patent expiration is determined from the applicable earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and any relevant continuation or divisional relationship. The May 24, 2011 issue date does not determine the expiration date.

The patent's commercial value therefore depends on the USPTO term record, not simply on the number printed on the patent. A drug patent may remain listed after issuance but have limited practical value if its term has expired, if the relevant product has moved to a different formulation, or if later continuation patents protect the marketed product.

No biologic exclusivity analysis applies. Any regulatory exclusivity would arise under the NDA framework, not the biosimilar framework.

What generic launch risks exist?

A generic or authorized-generic strategy would face the greatest risk where the proposed product has all of the following characteristics:

10 to 600 micrograms of desmopressin measured as free base;
a solid orodispersible dosage form;
disintegration within 10 seconds;
sublingual labeling;
a lyophilized open matrix;
gelatin or fish gelatin; and
packaging that instructs sublingual placement.

A lower-risk formulation strategy could use a conventional compressed tablet, a non-orodispersible product, a different dose, a different route, or a different clinical presentation. Those approaches may reduce patent exposure but can create separate bioequivalence, labeling, safety, or regulatory issues.

A Paragraph IV challenge would likely focus on one or more of the following:

anticipation by an earlier rapidly dissolving desmopressin dosage form;
obviousness based on known desmopressin formulations and lyophilized oral matrices;
indefiniteness of “disintegrates in the mouth within 10 seconds”;
written-description or enablement issues for the full dose range and carrier scope;
noninfringement based on dose, disintegration time, manufacturing route, or matrix structure; and
lack of infringement by a conventional tablet or non-sublingual product.

What patent litigation and settlement issues matter?

Potential litigation would likely center on testing and claim construction rather than the identity of the active ingredient. The principal evidentiary disputes would involve:

the assay used to measure desmopressin as free base;
whether acetate salt and hydrate content are included in the dose calculation;
the definition of “disintegrates”;
the test conditions used to establish 10-second performance;
whether the product has an “open matrix network”;
whether the carrier is inert toward desmopressin;
whether fish gelatin is non-gelling; and
whether the product was manufactured by sublimation or freeze drying.

Settlement terms in a Paragraph IV case could include a permitted generic launch date, supply or licensing rights, an authorized-generic arrangement, or restrictions tied to a particular dosage form. The patent claims themselves do not disclose any settlement, license, or court ruling.

Geographic coverage and manufacturing barriers

US 7,947,654 provides protection only in the United States. Parallel protection would require corresponding patents in other jurisdictions, such as European national patents, the United Kingdom, Canada, Japan, or Australia. Foreign claim scope, prosecution amendments, term, and validity may differ materially.

The manufacturing barrier is highest for a stable, low-dose lyophilized product that must meet a rapid-disintegration specification while preserving desmopressin potency. Relevant technical barriers include:

uniform distribution of microgram quantities of peptide;
control of residual moisture;
protection against degradation during freeze drying;
matrix strength sufficient for packaging and handling;
rapid wetting and dispersion;
taste and patient acceptability; and
dose uniformity across the batch.

Those manufacturing difficulties can create commercial barriers even where a competitor designs around the patent claims.

Key takeaways

US 7,947,654 is directed to low-dose, solid, rapidly disintegrating desmopressin dosage forms.
Claim 1 is the primary commercial claim and does not require freeze drying, gelatin, fish gelatin, or sublingual labeling.
Claims 3 and 4 focus on sublimation and freeze-drying processes.
Claims 5 through 8 protect increasingly specific open-matrix and gelatin technologies.
Claim 9 targets packaging with sublingual administration instructions.
Conventional tablets, liquids, nasal sprays, and injectables generally fall outside the principal claim.
Biosimilar litigation is not the relevant competitive pathway because desmopressin is a chemically defined small molecule.
Generic exposure is highest for low-dose lyophilized orodispersible products that disintegrate within 10 seconds.
Orange Book listing, Paragraph IV activity, litigation, settlement status, and current patent enforceability cannot be established from the claim text alone.
Patent-term analysis must use the USPTO prosecution and term-adjustment record rather than the 2011 issue date.

FAQs

Does US 7,947,654 cover all desmopressin tablets?

No. It covers a solid orodispersible dosage form within the specified dose range that disintegrates in the mouth within 10 seconds. Conventional swallowed tablets may fall outside the claim.

Does a product have to contain fish gelatin to infringe?

No. Fish gelatin is required only by claims 7 and 8. A product using another carrier could still implicate claim 1 or claim 5.

Is a freeze-dried desmopressin product automatically covered?

No. It must also satisfy the dose, solid-orodispersible, and 10-second disintegration requirements of claim 1. Claims 3 and 4 add specific process limitations.

Is an orally disintegrating tablet the same as a sublingual tablet under this patent?

Not necessarily. Claim 1 covers an orodispersible form without requiring sublingual use. Claim 2 and claim 9 add sublingual administration requirements.

Can a generic company avoid the patent by changing the desmopressin salt?

Not necessarily. The claim measures the active ingredient as desmopressin free base. Changing the salt may not avoid the dose limitation if the resulting product remains within the claimed free-base range.

References

United States Patent and Trademark Office. (2011). U.S. Patent No. 7,947,654, pharmaceutical dosage form.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Food and Drug Administration. (n.d.). Approved drug labeling and regulatory information for desmopressin products.
United States Code. (2024). 35 U.S.C. §§ 154, 156, and 271.
United States Code. (2024). 21 U.S.C. § 355 and 42 U.S.C. § 262.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0210397.6	May 7, 2002
	PCT/IB02/04036	Sep 20, 2002

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	039092	⤷ Start Trial
Argentina	039794	⤷ Start Trial
Argentina	107948	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,947,654

Summary for Patent: 7,947,654